Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 74,57 € (+9,04 %). La mediana es de 77,68 € (+13,58 %).
| Comprar |
11 |
| Mantener |
0 |
| Vender |
0 |
Noticias Ir al feed de noticias
Kiniksa Pharmaceuticals International names Ross Moat COO and Eben Tessari chief strategy officer
Kiniksa Pharmaceuticals International’s board has appointed Ross Moat as chief operating officer effective Friday; Moat will also remain responsible for commercial activities. Eben Tessari was named chief strategy officer and will continue to lead strategy, business development and technical operations as well as the company’s AI initiatives. Both appointments involve no changes to compensation arrangements; Kiniksa is headquartered in London and trades on Nasdaq under the ticker KNSA. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 213,44 M | 60,45 % |
| Beneficio bruto | 115,62 M | 58,90 % |
| Beneficio neto | 22,28 M | 47,29 % |
| EBITDA | 24,24 M | 22,97 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 5214,58 M € |
Número de acciones | 76,21 M |
Máximo/mínimo de 52 semanas | 71,59 € - 28,87 € |
| Dividendos | No |
Beta | 0,09 |
Ratio P/E | 74,09 |
Ratio PEG | 0,04 |
Ratio P/B | 9,40 |
Ratio P/S | 7,19 |
Perfil de la empresa
| Nombre | Kiniksa Pharmaceuticals International PLC Class A |
| CEO | Sanj K. Patel |
| Sede | London,
gl Reino Unido |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Empleados | 366 |
Descubrir activos
Los accionistas de Kiniksa Pharmaceuticals International PLC Class A también invierten en los siguientes activos
